CVRx (NASDAQ:CVRX) Announces Earnings Results

CVRx (NASDAQ:CVRX) posted its earnings results on Tuesday. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06), Zacks reports. CVRx had a negative return on equity of 89.06% and a negative net margin of 123.75%.

CVRx Stock Performance

NASDAQ:CVRX traded down $0.24 during midday trading on Thursday, reaching $14.84. 15,643 shares of the company traded hands, compared to its average volume of 263,244. CVRx has a twelve month low of $6.40 and a twelve month high of $25.03. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. The company has a fifty day moving average price of $14.71 and a 200 day moving average price of $11.73. The firm has a market capitalization of $360.02 million, a price-to-earnings ratio of -5.50 and a beta of 1.29.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. William Blair upgraded CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. Canaccord Genuity Group raised their price objective on CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler raised their price objective on CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday. Craig Hallum raised their price objective on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Finally, Lake Street Capital raised their price objective on CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.83.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.